GammaDelta Therapeutics

GammaDelta Therapeutics is a UK headquartered biotechnology company founded upon world-class academic research conducted by Professor Adrian Hayday and Dr Oliver Nussbaumer, at King’s College London and the Francis Crick Institute and supported by Cancer Research Technology. GammaDelta Therapeutics aims to harness the unique properties of γδ T cells to improve patient outcomes and survival rates among patients with haematological malignancies and solid tumours. Our mission is to deliver highly effective allogeneic immunotherapies based on the unique properties of Vδ1+ T cells with potential to provide additional benefits towards patient survival in the treatment of cancers. Our proprietary isolation and expansion protocols have the ability to selectively generate Vδ1+ T cell populations suitable for clinical application. The Company’s technologies are based upon pioneering world-class research conducted by Professor Adrian Hayday and Dr Oliver Nussbaumer, at King’s College London and the Francis Crick Institute, and Professor Bruno Silva-Santos at the University of Lisbon. GammaDelta’s technology has been recognised for its therapeutic potential, attracting interest from the pharmaceutical industry and investment from Takeda Pharmaceutical Company Limited and Abingworth LLP.